Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

December 26, 2022
Otsuka Medical Devices

Otsuka Medical Devices has entered into an exclusive agreement with CSI to distribute Diamondback 360 Coronary Orbital Atherectomy System in Japan
December 13, 2022
Otsuka Holdings

Otsuka Group Selected for CDP Climate Change A List
December 12, 2022
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory launches Lilium one, a medical device that measures urine volume in the bladder specialized for single measurement
December 6, 2022
Otsuka Pharmaceutical

Announcement of Price Revisions for Specified Products
December 5, 2022
Otsuka Pharmaceutical

Otsuka Pharmaceutical Tokushima Itano Factory Receives 2022 Minister of Economy, Trade and Industry Award for Excellent Greening
November 30, 2022
Otsuka Medical Devices

Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration
November 24, 2022
Taiho Pharmaceutical

Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Positive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1
November 24, 2022
Otsuka Pharmaceutical

New skin care brand Introducing Sakuraé Double Action Serum – Japan’s first ‟double brightening”effect –
November 21, 2022
Otsuka Pharmaceutical

Favorable Decision of the Supreme Court on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
November 21, 2022
Otsuka Medical Devices

Otsuka Medical Devices certified to ISO 13485
November 21, 2022
Otsuka Pharmaceutical Factory

Announcement of price revisions for the Oral Rehydration Solution OS-1 series
November 16, 2022
Otsuka Pharmaceutical

Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
November 10, 2022
Otsuka Pharmaceutical

Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for NY-ESO-1・siTCR® gene therapy candidate
November 7, 2022
Otsuka Pharmaceutical

Otsuka Opens Osaka Research Center for Drug Discovery in Osaka Prefecture, Japan
November 7, 2022
Otsuka Medical Devices

Announced Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022
October 24, 2022
Otsuka Pharmaceutical

Avanir Pharmaceuticals, Inc. Business Will Be Integrated Into Otsuka America Pharmaceuticals, Inc. as of January,1, 2023
October 11, 2022
Otsuka Pharmaceutical

Otsuka Pharmaceutical Supports Tokyo Legacy Half Marathon 2022 　Helping runners to complete the distance and set new records
October 10, 2022
Otsuka Pharmaceutical

Otsuka and Jolly Good to Launch FACEDUO, a Virtual Reality Support Program for Patients with Schizophrenia and Their Supporters
October 7, 2022
Otsuka Medical Devices

BioMimics 3D Vascular Stent System granted Good Design Award 2022
October 6, 2022
Taiho Pharmaceutical

Taiho Pharmaceutical Adds New Measures to Reduce Smoking Among Employees to Zero by 2023
October 4, 2022
Otsuka Pharmaceutical

Announcement of Price Revisions for Applicable Products
October 3, 2022
Taiho Pharmaceutical

U.S. FDA Approves FGFR Inhibitor, Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
September 28, 2022
Otsuka Pharmaceutical

Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit
September 27, 2022
Otsuka Pharmaceutical

Launch of OTSUKA BLUE PLANET in Indonesia Sustainability Program Aims to Contribute to Local Environmental Efforts
September 20, 2022
Otsuka Pharmaceutical

Otsuka announces EC approval of Lupkynis® (voclosporin) as first oral treatment for active lupus nephritis
September 20, 2022
Otsuka Medical Devices

Otsuka Medical Devices Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting
September 14, 2022
Otsuka Pharmaceutical

Launch of SOYJOY Sweet Potato Popular ingredient flavors new whole-soy nutrition bar
September 13, 2022
Otsuka Pharmaceutical

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults
September 13, 2022
Taiho Pharmaceutical

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer
September 12, 2022
Otsuka Pharmaceutical

Otsuka Pharmaceutical announces positive results of phase III　trial in Japan for brexpiprazole in the treatment of major depressive disorder